Beverly Hills Cancer Center
Beverly Hills, CA
Accepting patients
MagnetisMM-32
Phase 3 Clinical Trial Comparing the Safety and Effectiveness of Elranatamab Versus Commonly Used Combination Regimens in Participants with Relapsed/Refractory Multiple Myeloma
- Bispecific Antibody
- BCMA
- Phase 3
Accepting patients
MagnetisMM-20
Phase 1B Study Evaluating Elranatamab in Combination with Carfilzomib/Dexamethasone or in Combination with PF-07901801 (maplirpacept) in Relapsed/Refractory Multiple Myeloma
- Bispecific Antibody
- BCMA
- Phase 1
- Has results
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trialsAccepting patients
DREAMM13
A Phase I Study of Belantamab Mafodotin in Multiple Myeloma Participants with Normal and Impaired Hepatic Function
- Antibody Drug Conjugate (ADC)
- BCMA
- Phase 1
Accepting patients
MagnetisMM-4
MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma
- Bispecific Antibody
- Gamma-Secretase Inhibitor
- BCMA
- Phase 1/2